linjc16/ctgov huggingface dataset:
Ear Acupuncture for Acute Sore Throat.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare ear acupuncture plus standard of care versus standard therapy (anti-inflammatory medications) in the reduction of pain, reduction in oral anti inflammatory medication use, hours lost from work in acute sore throat.

Official Title
-----------------
Ear Acupuncture for Acute Sore Throat. A Randomized Controlled Trial.

Conditions
-----------------
Acute Sore Throat

Intervention / Treatment
-----------------
* Device: Standard treatment plus ear acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Male and female subjects (DoD beneficiaries), 18 years or older, with upper respiratory complaints and their primary symptom being acute sore throat. Minimum pain score of 5 points on an 11 point scale (0-10 with 10 being the worst pain) Exclusion: History of significant gastrointestinal bleed Previous documented history of stage 2 kidney disease or worse Known Pregnancy History of gastric bypass surgery Known Peritonsillar abscess (PTA) Throat, mouth or esophageal cancer Chronic oral steroids use Absence of one or more ears Active cellulitis of ear Ear anatomy precluding identification of acupuncture landmarks Non-English speaking Use of Hearing Aids that preclude the use of ear acupuncture Allergy to Ibuprofen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: battlefield auricular acupuncture<br>battlefield auricular acupuncture | Device: Standard treatment plus ear acupuncture<br>* Standard treatment plus ear acupuncture<br>* Other names: Sedatelec ASP Original Gold needles;|
| No Intervention: placebo<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Pain | Subjects will be randomized to receive either standard treatment alone or standard treatment plus ear acupuncture. Subjects will be asked 15 minutes after their treatment to assess their pain on a scale of 0-10. After the subject has left the clinic, phone calls will be made at 6 hours, 24 hours and 48 hours to assess their pain level, ask about their missed hours from work, and ask the number of doses of ibuprofen taken. Subjects who report back after 48 hours with unimproved sore throat will be instructed to make a same day follow up with the clinic. | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Sore Throat, Ear Acupuncture
A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter

Study Overview
=================
Brief Summary
-----------------
Hypothesis: The induction of labor in patients with unfavorable Bishop score is a challenging obstetrical process, and may be influenced or complicated by the cervical ripening method used. We will conduct a comparative study of the foley catheter vs the cervical ripening double balloon (Cook medical, GPN: G48149). We will compare the failure rates, cesarean section rate, infections and postpartum complications, especially endometritis.

Detailed Description
-----------------
We will conduct a comparative study of the foley catheter vs the cervical ripening double balloon (Cook medical, GPN: G48149). We will compare the failure rates, cesarean section rate, infections and postpartum complications, especially endometritis. The study will include 200 parturients, 100 primiparous and 100 multiparous women. We will randomize each group to induction with the foley catheter or the cervical ripening double balloon. We will compare the failure rates, cesarean section rate, infectious and other postpartum complications, especially endometritis.

Official Title
-----------------
A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter

Conditions
-----------------
Induction of Labor, Cesarean, Endometritis

Intervention / Treatment
-----------------
* Device: Mechanical induction of labor
* Device: Double Balloon
* Device: Foley Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term pregnancy Parturients candidates for mechanical induction of labor Exclusion Criteria: Suspected amnionitis Vaginal discharge Pre induction pyrexia Immunocompromised parturients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Mechanical induction of labor|nan|
|Device: Double Balloon|nan|
|Device: Foley Catheter|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of labor induction |  | Postpartum period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postpartum endometritis rate |  | The postpartum period | 
| Cesarean section rate |  | Delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Induction of labor, Cesarean, Endometritis, Foley, Infections
Effect of Cervical Immobilization on Optic Nerve Sheath Diameter

Study Overview
=================
Brief Summary
-----------------
Effect of Cervical Immobilization on Optic Nerve Sheath Diameter

Detailed Description
-----------------
Two cervical immobilization devices will be used in this study named cervical neck collar and head blocks strapped on the backboard and optic nerve diameter will be measured using point of care ultrasound and compare the effect of each type of cervical immobilisation on optic nerve sheath diameter.

Official Title
-----------------
Effect of Cervical Neck Collar and Head Blocks Strapped on the Backboard on Optic Nerve Sheath Diameter

Conditions
-----------------
Optic Nerve Sheath Diameter, Point of Care Ultrasound

Intervention / Treatment
-----------------
* Device: cervical neck collar


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult healthy volunteers aged more than 18 years Exclusion Criteria: Hx of stroke Inability to consent, Inability to lay flat on a bed or table for 15 min in duration, History of glaucoma, globe injury, lens implant, Recent refractive surgery (within the past 60 days). Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cervical neck collar<br> | Device: cervical neck collar<br>* devices used for cervical immobilization<br>* Other names: head blocks strapped on the backboard;|
| head blocks strapped on the backboard<br> | Device: cervical neck collar<br>* devices used for cervical immobilization<br>* Other names: head blocks strapped on the backboard;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of cervical neck collar and head blocks strapped on the backboard on Optic Nerve Sheath Diameter | effect of cervical neck collar and head blocks strapped on the backboard on optic nerve sheath diameter, measured by point of care ultrasound | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervical immobilization
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast

Study Overview
=================
Brief Summary
-----------------
To determine the ability of magnetic resonance lymphangiography using conventional gadolinium injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis in patients with newly diagnosed H&N cancers

Official Title
-----------------
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast

Conditions
-----------------
Head and Neck Cancer, Head and Neck Cancers

Intervention / Treatment
-----------------
* Procedure: IMR LAG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Patients with newly diagnosed squamous cell carcinomas of the H&N with primary tumor sites that are accessible to direct contrast injections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: IMR LAG|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determined the ability of magnetic resonance lymphangiography using conventional gadolinium injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis in patients with newly diagnosed H&N cancers |  |  |
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Study Overview
=================
Brief Summary
-----------------
To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Detailed Description
-----------------
Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Official Title
-----------------
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Conditions
-----------------
Hodgkin Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Details held in the ADAPT database at The Christie NHS Foundation trust Responded to most recent ADAPT study questionnaire (April - August 2019) Aged 18-80 Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years Able to provide informed consent Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy. Exclusion Criteria: Previous or current diagnosis of lung cancer Stated within 2019 health questionnaire that they did not wish to be contacted Have participated in lung cancer screening through the Manchester Lung Health Checks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Explore survivors' attitudes towards lung cancer and lung cancer screening | Semi-structured interviews | 6 months |
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.

Official Title
-----------------
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

Conditions
-----------------
Colon Cancer, Head and Neck Cancer, Allergic Reaction

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient informed consent, Patient aged over 18 years Patients with a WHO performance status ≤ 2, Colon cancer or upper aero-digestive tract cytologically or histologically proven Patients with an indication to the theoretical use of cetuximab for colon neoplasia or upper aero-digestive tract, Haematological and biochemical compatible with combination therapy with cetuximab. Exclusion Criteria: Patients previously treated with cetuximab, A person deprived of liberty or under supervision.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validate the utility of an IgE anti-cetuximab test in the treatment strategy | We hypothesize that a positive specific IgE assay predicts the occurrence of an allergic reaction during the first dose of cetuximab. Thus, in population areas where the prevalence of specific IgE positive plasma is higher, the use of alternative therapies in patients with a positive test would reduce the incidence of anaphylactic reactions to cetuximab. If the use of specific IgE anti-cetuximab in the treatment strategy is effective, there will be reduction in the incidence of anaphylaxis to cetuximab in the participating centers. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon, cancer, Head and neck, cetuximab, anti-cetuximab dosage
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).

Detailed Description
-----------------
In this open-label pilot study, patients are randomized to 1of the following 4 arms for 24 weeks: Arm 1 (40 patients): DLV plus ZDV plus IDV. Arm 2 (40 patients): DLV plus IDV plus 3TC*. Arm 3 (40 patients): DLV plus ZDV plus IDV plus 3TC. Arm 4 (40 patients): ZDV plus IDV plus 3TC. Dose determined by body weight. Patients may opt to continue on study for 24 additional weeks at the discretion of the investigator.

Official Title
-----------------
An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Indinavir sulfate
* Drug: Delavirdine mesylate
* Drug: Lamivudine
* Drug: Zidovudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Prior Medication: Allowed: Less than 1 month prior treatment with zidovudine. Exclusion Criteria Prior Medication: Excluded: Prior indinavir. Prior lamivudine. Prior protease inhibitors. Prior non-nucleoside reverse transcriptase inhibitors. 1 month or more prior zidovudine. 1. HIV-1 positive. CD4 coun tis above 50. HIV-1 RNA levels greater than 20,000.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indinavir sulfate|nan|
|Drug: Delavirdine mesylate|nan|
|Drug: Lamivudine|nan|
|Drug: Zidovudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-1, Zidovudine, HIV Protease Inhibitors, Lamivudine, Indinavir, RNA, Viral, Delavirdine, Reverse Transcriptase Inhibitors, Viral Load
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

Study Overview
=================
Brief Summary
-----------------
Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.

Detailed Description
-----------------
In Germany ovarian cancer belongs to the most frequently forms of cancer in the female population. The prognosis for women with a platin refractory ovarian cancer is very bad. The median survival time amounts for less a year. Especially in this palliative situation therapies regarding efficacy as well as quality of life are needed. in Germany Topotecan is approved since 1996 for patients after previous treatment with platin, the rare non-hematological side-effects making it interesting for a palliative therapy. Since best results in a chemo-therapeutical treatment are commonly obtained with the combination of two or more cytostatic agents this study tests a Topotecan Monotherapy and two Topotecan combinations. Both combination agents show efficacy alone against solid cancer using from Topotecan different mechanism resulting in different main side effects. Total survival, remission rates, time ti progression and quality of life are the main criteria investigated.

Official Title
-----------------
Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs. Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Drug: Hycamtin
* Drug: Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with recurrent ovarian cancer Second-line chemotherapy > = 18 years of age ECOG < = 2 Exclusion Criteria: ECOG > 2 Patients with more than one chemotherapy in anamneses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Hycamtin|nan|
|Drug: Gemcitabine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to progression |  |  | 
| determining adverse effects |  |  | 
| quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian cancer
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

Study Overview
=================
Brief Summary
-----------------
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.

Official Title
-----------------
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Procedure: Bone Marrow Aspiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:1. All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible. There is no bias in regards to age range, gender or ethnic background. 2. Signed informed consent

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Bone Marrow Aspiration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene Expression |  | days 0, 8, 22 or 29 |